2/9/2021 7:11:33 AM
Incyte Q4 GAAP EPS $0.68; Non-GAAP EPS $0.93
1/5/2021 2:02:54 AM
MorphoSys, Incyte Report That Swissmedic Accepted MAA For Tafasitamab
12/30/2020 7:41:59 AM
Incyte, Cellenkos Announce Collaboration To Investigate Combination Of Ruxolitinib And CK0804
12/14/2020 1:29:58 AM
Incyte Says Phase 3 RUXCOVID Study Evaluating Ruxolitinib Did Not Meet Its Primary Endpoint
12/8/2020 7:51:08 AM
William Blair Is Increasing Incyte Corporation (INCY) FY22 Rev. Estimate To 3.40 Billion From 3.39 Billion
12/8/2020 7:50:49 AM
William Blair Is Raising Incyte Corporation (INCY) FY21 Rev. Estimate To 2.860 Billion From 2.857 Billion
12/8/2020 7:49:50 AM
William Blair Is Increasing Incyte Corporation (INCY) FY22 Estimate To 4.71 From 4.69
12/8/2020 7:49:22 AM
William Blair Is Increasing Incyte Corporation (INCY) FY20 Estimate To -0.58 From -0.66
12/8/2020 7:47:23 AM
William Blair Reiterates Incyte Corporation (INCY) At Outperform
12/7/2020 10:05:06 AM
Incyte Says Data From CITADEL Studies Presented At ASH 2020 Are Very Promising